The Institute for Clinical and Economic Review (ICER) evaluated the clinical and economic outcomes of aducanumab for AD. In this review,
we present a summary of our findings and highlight key policy recommendations discussed at the California Technology Assessment Forum’s public meeting on July 15, 2021. Complete details of ICER’s assessment are available at